1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Tuberculosis Treatment Market
2.2. Global Tuberculosis Treatment Market, By Drug Class, 2023 (US$ Million)
2.3. Global Tuberculosis Treatment Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Tuberculosis Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Tuberculosis Treatment Market Vendors
3.2. Strategies Adopted by Tuberculosis Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032

4. Tuberculosis Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Tuberculosis Treatment Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. First line Treatment
5.3.1.1. Cytochrome P450 inhibitor (Isoniazid)
5.3.1.2. Mycolic acid inhibitor (Ethambutol)
5.3.1.3. FAS I inhibitor (Pyrazinamide)
5.3.1.4. RNA polymerase inhibitor (Rifampin)
5.3.2. Second Line Treatment
5.3.2.1. Mycolic acid inhibitor (Ethionamide)
5.3.2.2. Peptidoglycans inhibitor (Cycloserine)
5.3.2.3. Folic acid inhibitor (Para-amino salicylic acid)
5.3.2.4. 30S ribosome inhibitor (Kanamycin)


6. North America Tuberculosis Treatment Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
6.3.Tuberculosis Treatment Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)

7. UK and European Union Tuberculosis Treatment Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.3.Tuberculosis Treatment Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)

8. Asia Pacific Tuberculosis Treatment Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.3.Tuberculosis Treatment Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)

9. Latin America Tuberculosis Treatment Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
9.3.Tuberculosis Treatment Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)

10. Middle East and Africa Tuberculosis Treatment Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
10.3.Tuberculosis Treatment Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Tuberculosis Treatment Market: By Drug Class, 2022-2032, USD (Million)

11. Company Profile
11.1. Bayer Healthcare
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Eli Lilly & Co.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Labatec Pharma SA
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Macleods Pharmaceuticals Pvt Ltd.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Mylan N.V.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Novatis AG
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Otsuka Novel Products GmbH
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Patheon, Inc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Pfizer, Inc.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Sanofi S.A.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives